Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 23.
doi: 10.1038/s41372-025-02417-8. Online ahead of print.

Comparison of neurodevelopmental outcomes of extremely preterm infants undergoing trans-catheter closure of the patent ductus arteriosus compared to surgical ligation

Affiliations

Comparison of neurodevelopmental outcomes of extremely preterm infants undergoing trans-catheter closure of the patent ductus arteriosus compared to surgical ligation

D C Kaluarachchi et al. J Perinatol. .

Abstract

Background: There is a paucity of data on neurodevelopmental outcomes in preterm infants who undergo transcatheter patent ductus arteriosus (PDA) closure (TCPC).

Objective: To evaluate neurodevelopmental impairment (NDI) or death at 2 years among preterm infants treated with TCPC compared to surgical ligation.

Methods: Retrospective cohort study of infants born at <27 weeks' gestation at NICHD NRN sites. Comparisons were made between infants who underwent TCPC and PDA ligation.

Results: TCPC and surgical ligation were performed on 99 and 279 infants, respectively. Death or severe NDI occurred in 49% of infants with TCPC and 40% with surgical ligation. There was no difference in odds of death or severe NDI between the two groups [aOR 1.12 95% CI: 0.55-2.26)].

Conclusion: TCPC had similar odds of death or severe NDI compared to surgical ligation. These findings need to be evaluated in large prospective studies as the management practice around the TCPC evolves.

Clinical trial registration: ClinicalTrials.gov ID: Generic Database: NCT00063063.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Kaluarachchi serves as a consultant for ONY Biotech Inc. Dr. Backes has following disclosures—Abbott Laboratories: funding of ongoing multicenter trial, in partnership with National Institutes of Health, entitled PIVOTAL (NCT05547165). Abbott Laboratories has no part in the design or execution of PIVOTAL. Dr. McNamara serves as a consultant for Aspect Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Kaluarachchi DC, Rysavy MA, Carper BA, Chock VY, Laughon MM, Backes CH, et al. Secular Trends in Patent Ductus Arteriosus Management in Infants Born Preterm in the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 2024;266:113877. - DOI - PubMed
    1. Lai KC, Richardson T, Berman D, DeMauro SB, King BC, Lagatta J, et al. Current Trends in Invasive Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants in United States Children’s Hospitals, 2016-2021. J Pediatr. 2023;263:113712. - DOI - PubMed
    1. Shah ZS, Clark RH, Patt HA, Backes CH Jr, Tolia VN. Trends in Procedural Closure of the Patent Ductus Arteriosus among Infants Born at 22 to 30 Weeks’ Gestation. J Pediatr. 2023;263:113716. - DOI - PubMed
    1. Clyman RI, Benitz WE. Trans catheter patent ductus arteriosus closure— will history repeat itself? J Perinatol. 2019;39:1435–6. - DOI - PubMed
    1. Backes CH, Giesinger RE, Rivera BK, Berman DP, Smith CV, Cua CL, et al. Percutaneous closure of the patent ductus arteriosus in very low weight infants: considerations following US Food and Drug Administration approval of a novel device. J Pediatr. 2019;213:218–21. - DOI - PubMed

Associated data

LinkOut - more resources